A detailed history of Virtus ETF Advisers LLC transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 19,651 shares of TGTX stock, worth $550,228. This represents 0.22% of its overall portfolio holdings.

Number of Shares
19,651
Previous 19,651 -0.0%
Holding current value
$550,228
Previous $349,000 31.52%
% of portfolio
0.22%
Previous 0.18%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$13.32 - $19.19 $197,615 - $284,702
14,836 Added 308.12%
19,651 $349,000
Q1 2024

May 15, 2024

SELL
$13.02 - $21.3 $4,270 - $6,986
-328 Reduced 6.38%
4,815 $73,000
Q4 2023

Feb 15, 2024

BUY
$6.68 - $18.81 $10,080 - $28,384
1,509 Added 41.52%
5,143 $87,000
Q3 2023

Nov 07, 2023

SELL
$8.36 - $26.5 $3,068 - $9,725
-367 Reduced 9.17%
3,634 $30,000
Q2 2023

Aug 14, 2023

SELL
$15.48 - $35.0 $109,180 - $246,855
-7,053 Reduced 63.8%
4,001 $99,000
Q1 2023

May 15, 2023

SELL
$10.23 - $19.34 $43,518 - $82,272
-4,254 Reduced 27.79%
11,054 $166,000
Q4 2022

Feb 14, 2023

SELL
$5.01 - $11.83 $59,253 - $139,913
-11,827 Reduced 43.59%
15,308 $181,000
Q3 2022

Nov 14, 2022

BUY
$4.57 - $8.4 $914 - $1,680
200 Added 0.74%
27,135 $161,000
Q2 2022

Aug 12, 2022

BUY
$3.74 - $10.66 $63,557 - $181,156
16,994 Added 170.95%
26,935 $114,000
Q1 2022

May 16, 2022

SELL
$7.81 - $20.45 $4,646 - $12,167
-595 Reduced 5.65%
9,941 $95,000
Q4 2021

Feb 14, 2022

BUY
$15.2 - $35.51 $75,802 - $177,088
4,987 Added 89.87%
10,536 $200,000
Q3 2021

Nov 15, 2021

SELL
$21.78 - $40.45 $6,337 - $11,770
-291 Reduced 4.98%
5,549 $185,000
Q2 2021

Aug 10, 2021

SELL
$32.5 - $48.96 $33,410 - $50,330
-1,028 Reduced 14.97%
5,840 $227,000
Q1 2021

May 17, 2021

BUY
$41.61 - $54.3 $5,201 - $6,787
125 Added 1.85%
6,868 $331,000
Q4 2020

Feb 12, 2021

SELL
$25.27 - $54.9 $282,468 - $613,672
-11,178 Reduced 62.37%
6,743 $351,000
Q3 2020

Nov 13, 2020

SELL
$18.49 - $27.24 $45,503 - $67,037
-2,461 Reduced 12.07%
17,921 $480,000
Q2 2020

Aug 05, 2020

SELL
$8.9 - $21.84 $135,493 - $332,492
-15,224 Reduced 42.76%
20,382 $397,000
Q1 2020

May 14, 2020

SELL
$7.14 - $15.99 $37,006 - $82,876
-5,183 Reduced 12.71%
35,606 $350,000
Q4 2019

Feb 13, 2020

BUY
$5.1 - $11.2 $30,528 - $67,043
5,986 Added 17.2%
40,789 $453,000
Q3 2019

Nov 12, 2019

SELL
$5.38 - $8.99 $10,426 - $17,422
-1,938 Reduced 5.27%
34,803 $195,000
Q2 2019

Aug 13, 2019

SELL
$6.27 - $8.65 $107,856 - $148,797
-17,202 Reduced 31.89%
36,741 $318,000
Q1 2019

May 14, 2019

SELL
$4.02 - $8.04 $30,608 - $61,216
-7,614 Reduced 12.37%
53,943 $434,000
Q4 2018

Feb 05, 2019

BUY
$3.44 - $5.76 $93,340 - $156,291
27,134 Added 78.83%
61,557 $252,000
Q3 2018

Nov 14, 2018

SELL
$5.15 - $14.0 $126,684 - $344,386
-24,599 Reduced 41.68%
34,423 $193,000
Q2 2018

Aug 10, 2018

SELL
$12.5 - $15.0 $386,225 - $463,470
-30,898 Reduced 34.36%
59,022 $776,000
Q1 2018

May 14, 2018

BUY
$8.7 - $16.8 $418,356 - $807,861
48,087 Added 114.95%
89,920 $1.28 Million
Q4 2017

Feb 14, 2018

BUY
$7.35 - $12.3 $90,993 - $152,274
12,380 Added 42.03%
41,833 $343,000
Q3 2017

Nov 14, 2017

BUY
$10.0 - $12.7 $26,940 - $34,213
2,694 Added 10.07%
29,453 $349,000
Q2 2017

Aug 14, 2017

BUY
N/A
26,759
26,759 $269,000

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.07B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.